To prepare for the next coronavirus outbreak, vaccines need to be developed that can be produced quickly, stockpiled effectively, and distributed efficiently. A clear limitation of the current vaccines is the difficulty of worldwide distribution, requiring a cold or ultra-cold chain. This work’s overall goal is to develop dry formulations of two vaccines, a Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein and a VLP vaccine antigen, and demonstrate their stability to a vaccine vial monitors category type 14 (VVM14) stability level. This will be achieved using a scalable spray drying process that avoids the known limitations of lyophilization. The planned work will require 12 months and will be performed through three main tasks.
The objectives of the proposed work are:
This project will facilitate the development of stable vaccine candidates that do not require a cold chain, allowing them to be quickly, inexpensively, and easily distributed in future coronavirus outbreak, rapidly getting the vaccine to those in need.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.